Lota Zoth - Spark Therapeutics Director
Director
Ms. Lota S. Zoth, CPA, is Independent Director of Spark Therapeutics, Inc. Ms. Zoth has served in senior financial roles in a variety of commercialstage companies over a 30year career, including serving as Chief Financial Officer of MedImmune Inc., or Medimmune, from 2002 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporationrationrate Controller and Principal Accounting Officer at PSINet Inc., Vice President, Corporationrationrate Controller and Chief Accounting Officer at Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst Young, LLP and is a Certified Public Accountant since 2016.
| Age | 58 |
| Tenure | 8 years |
| Phone | 888 772-7560 |
| Web | www.sparktx.com |
Lota Zoth Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lota Zoth against Spark Therapeutics stock is an integral part of due diligence when investing in Spark Therapeutics. Lota Zoth insider activity provides valuable insight into whether Spark Therapeutics is net buyers or sellers over its current business cycle. Note, Spark Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Spark Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lota Zoth over six months ago Sale by Lota Zoth of 5700 shares of Inovio Pharmaceuticals |
Spark Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 138.01 M in liabilities with Debt to Equity (D/E) ratio of 34.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has a current ratio of 5.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Spark Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Spark Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spark Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spark to invest in growth at high rates of return. When we think about Spark Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Graham Clow | Barrick Gold Corp | 66 | |
| Vanessa Chang | Transocean | 67 | |
| Michael Grant | Seadrill Limited | 62 | |
| Safiatou BaNDaw | Barrick Gold Corp | 64 | |
| Jeanine Lioko | Barrick Gold Corp | 52 | |
| Chad Deaton | Transocean | 61 | |
| Pablo Marcet | Barrick Gold Corp | 53 | |
| Samuel Merksamer | Transocean | 40 | |
| Adam Piekarski | Independence Contract Drilling | 37 | |
| Harald Thorstein | Seadrill Limited | 37 | |
| Orjan Svanevik | Seadrill Limited | 50 | |
| Jonathan Rubenstein | Eldorado Gold Corp | 67 | |
| Ek Tan | Transocean | 71 | |
| Olivia Kirtley | Barrick Gold Corp | 66 | |
| Margareth Ovrum | Transocean | 62 | |
| Norborne Cole | Barrick Gold Corp | 73 | |
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Frederico Curado | Transocean | 59 | |
| KjellErik Ostdahl | Seadrill Limited | 52 | |
| Michael Price | Eldorado Gold Corp | 63 | |
| John Webster | Eldorado Gold Corp | 65 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 |
Spark Therapeutics Leadership Team
Elected by the shareholders, the Spark Therapeutics' board of directors comprises two types of representatives: Spark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spark. The board's role is to monitor Spark Therapeutics' management team and ensure that shareholders' interests are well served. Spark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Romuald Corbau, Translational Research Lead | ||
| Carol GrevePhilips, Head of Business Development and Strategy | ||
| Robert Perez, Director | ||
| Lars Ekman, Independent Director | ||
| Jennifer Wellman, Co-Founder and Head of Regulatory Strategy | ||
| Fraser Wright, Co-Founder and CTO | ||
| Morgan Molloy, Head of U.S. Commercial | ||
| Lorris Betz, Director | ||
| Joseph Barge, General Counsel and Head of Business Administration | ||
| Katherine High, President Chief Scientific Officer, Director | ||
| Elliot Sigal, Independent Director | ||
| John Furey, COO | ||
| Vincent Milano, Independent Director | ||
| Lota Zoth, Director | ||
| Rogerio Coelho, Chief Commercial Officer | ||
| Elliott Sigal, Independent Director | ||
| Guang Qu, Head of Process Development | ||
| Daniel Takefman, Head of Regulatory Affairs | ||
| Stephen Webster, CFO | ||
| Rogerio Vivaldi, Chief Commercial Officer | ||
| Diane Blumenthal, Head of Technical Operations | ||
| Jeffrey Marrazzo, CEO, Co-Founder, Director | ||
| Daniel Faga, Chief Business Officer | ||
| Anand Mehra, Independent Director | ||
| Linda Hearne, Financial Operations and Analysis Lead | ||
| Paul Gil, Regulatory CMC and Quality Assurance Lead | ||
| Charles Sigal, Independent Director | ||
| Federico Mingozzi, Chief Scientific Officer | ||
| Steven Altschuler, Chairman of the Board | ||
| Lisa Dalton, Head - Human Resources |
Spark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.0009) % | |||
| Current Valuation | 3.97 B | |||
| Shares Outstanding | 38.49 M | |||
| Shares Owned By Insiders | 7.45 % | |||
| Shares Owned By Institutions | 92.25 % | |||
| Number Of Shares Shorted | 3.47 M | |||
| Price To Earning | (13.29) X | |||
| Price To Book | 10.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spark Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spark Therapeutics' short interest history, or implied volatility extrapolated from Spark Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Spark Stock
If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |